B Rack1, V Heinemann, C Schindlbeck, J Walther, C Salat, H Sommer. Show Affiliations » 1. I. Frauenklinik der Universität München. brigitte.rack@med.uni-muenchen.de
Abstract
Entities: Disease
Mesh： See more » Angiogenesis Inhibitors/administration & dosageAngiogenesis Inhibitors/pharmacologyAngiogenesis Inhibitors/therapeutic useAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/pharmacologyAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAntineoplastic Agents/administration & dosageAntineoplastic Agents/adverse effectsAntineoplastic Agents/pharmacologyAntineoplastic Agents/therapeutic useAntineoplastic Combined Chemotherapy Protocols/therapeutic useBevacizumabBone Density Conservation Agents/administration & dosageBone Density Conservation Agents/adverse effectsBone Density Conservation Agents/pharmacologyBone Density Conservation Agents/therapeutic useBone Neoplasms/prevention & controlBone Neoplasms/secondaryBreast Neoplasms/diagnosisBreast Neoplasms/drug therapyBreast Neoplasms/mortalityClinical Trials, Phase III as TopicDiphosphonates/administration & dosageDiphosphonates/adverse effectsDiphosphonates/pharmacologyDiphosphonates/therapeutic useFemaleHistocytochemistryHumansLapatinibNeoplasm MetastasisOsteonecrosis/chemically inducedProtein Kinase Inhibitors/administration & dosageProtein Kinase Inhibitors/pharmacologyProtein Kinase Inhibitors/therapeutic useQuinazolines/administration & dosageQuinazolines/pharmacologyQuinazolines/therapeutic useReceptor, ErbB-2/drug effectsRisk FactorsSignal Transduction/drug effectsTime FactorsTrastuzumab
Substances： See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBone Density Conservation AgentsDiphosphonatesProtein Kinase InhibitorsQuinazolinesLapatinibBevacizumabReceptor, ErbB-2Trastuzumab
Year: 2008 PMID： 18300641 DOI： 10.1007/bf03365276
Source DB: PubMed Journal: MMW Fortschr Med ISSN： 1438-3276